ARCHIVES

Mass. Law Requires Reimbursement For Off-Label Cancer Drugs

This article is from The Cancer Letter archive.

Vol. 19 No. 04 | January 22, 1993

Download PDF Visit The Full Archive

Related Articles

FDA Official Outlines agency’s Views On Efficacy Requirement

June 16, 1999

FDA Oncology Division Director Says Goal to Make Review Process “Predictable”

August 2, 1996

Turmoil in Texas: SEC Issues Subpoena to AVEO on Tivozanib

July 12, 2013

Chabner Criticizes FDA Crackdown On Off-Label Info

June 28, 1991

Radiotherapy Plus Cetuximab May Control Head/Neck Cancer

November 26, 2010

Patient Advocacy: FDA, NCI Developing Methods For Naming Survivors To Boards

February 7, 1997